Par Pharmaceutical

  › Par pharmaceuticals chestnut ridge ny

 › Ku med hospital map

 › Mount carmel health plan medicare

 › One medical sf ca

 › Dependent shot records tricare

 › Small business health insurance law

 › Medicare secondary workers compensation

 › World health organization uganda

 › Cqc health and social care

 › Side effects & drug interactions

 › Pharmaceutical representative resume sample

 › United healthcare palliative care program

 › Company drug testing policy

 › Helio health administrative office

 › Orlando health policies and procedures

 › Major health issues in japan

 › Culturally competent nursing care guidelines

 › Michigan board of pharmacy ce

 › Sutter health network ca

 › Child health insurance program

 › Amita health on talcott in chicago

FAQ about Par Pharmaceutical

What does Par Pharmaceutical do?

Par Pharmaceutical specializes in modified-released oral solid dosage forms as well as non-oral dosage forms, such as nasal sprays, inhalers, patches and other alternative drug delivery platforms. Our focus is on therapeutically equivalent ANDA-based products, and others on a case-by-case basis.

How many drugs does Par Pharmaceutical sell?

Par Pharmaceutical, Inc. manufactures, markets and/or distributes more than 122 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.

Who is par sterile products?

Par Sterile Products develops, manufactures and markets a broad portfolio of branded and generic aseptic injectable products. With a sterile manufacturing facility located in Rochester, Michigan, Par Sterile Products possesses an unparalleled reputation for high-quality products and an impeccable record of regulatory compliance.

What is Endo International's acquisition of Par Pharmaceutical Holdings?

Ireland-based Endo International has completed the $8.05bn acquisition of US-based Par Pharmaceutical Holdings from private investment firm TPG Capital North America. The deal adds a quickly growing generics portfolio to its specialty offerings, and positions Endo as one of the five largest generic drug companies in the US based on annual sales.